Published in:
Open Access
01-12-2021 | Insomnia | Research article
Insomnia in adults with cystic fibrosis: strong association with anxiety/depression and impaired quality of life
Authors:
Pauline Mulette, Bruno Ravoninjatovo, Camille Guguen, Coralie Barbe, Julien Ancel, Sandra Dury, Antoine Dumazet, Dominique Perdu, Jeanne-Marie Perotin, Thomas Guillard, François Lebargy, Gaëtan Deslee, Claire Launois
Published in:
BMC Pulmonary Medicine
|
Issue 1/2021
Login to get access
Abstract
Background
While sleep disruption is a common complaint among children with cystic fibrosis (CF), only a few studies have investigated insomnia in adults. The aim of this study was to identify factors associated with insomnia in clinically stable adult CF patients.
Methods
Twenty-eight CF patients (18M/10F), with a median age of 27 (22–34) (median (interquartile range) years and a median of forced expiratory volume in one second of 72 (39–93) % predicted completed questionnaires on insomnia (Insomnia Severity Index, ISI), sleep quality (PSQI), daytime sleepiness (Epworth), restless legs syndrome (IRLS), pain (NRS), anxiety/depression (HAD) and quality of life (CFQ-R 14+). Respiratory assessment data, including symptoms, sputum analysis, arterial blood gases, 6-min walking test, pulmonary function tests and polysomnographic variables, were also analyzed.
Results
Forty-three percent of patients were insomniac (ISI > 7). Compared with non-insomniac patients (ISI ≤ 7), insomniac patients had more severely impaired quality of life and a higher HAD score: median anxiety score of 9 (8–11) vs 4 (3–6) (p < 0.0001), median depression score of 7 (5–10) vs 1 (1–4) (p < 0.001), with a positive correlation between ISI and HAD anxiety/depression scores (r = 0.702/r = 0.701, respectively, p < 0.0001). Insomnia was also associated with mMRC dyspnea scale ≥ 2, restless legs syndrome, pain and lower SpO2 during sleep.
Conclusions
The strong association between insomnia, impaired quality of life and increased HAD score should prompt physicians to be particularly attentive to the management of anxiety and depression in adult CF patients with insomnia.
Trial registration: On clinicaltrials.gov (NCT02924818, date of registration: October 5, 2016).